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Introduction
Much human research on vitamin D and asthmatic disease is now available. This second part of a two-part review will briefly introduce vitamin D and its sources. However, the main focus will be human evidence linking vitamin D to human asthma, including epidemiological, case-control, cross-sectional, prospective and intervention studies. We will discuss the merits and limitations of each study design regarding asthma and vitamin D. However, unanswered questions remain. We have reviewed mechanisms by which vitamin D may influence asthmatic disease in part one of this two-part review [92] . Therefore, we will conclude this review with some recommendations for future research in the area.
There are two major forms of fat-soluble vitamin D: vitamin D 2 (ergocalciferol) available from plant sources such as ultraviolet-B (UV-B) irradiated mushrooms and vitamin D 3 (cholecalciferol) available from animal sources such as oily fish and produced in human skin upon exposure to ultraviolet B radiation (UV-B). Although both forms of vitamin D are bioactive and available as a dietary supplement, it is recognized that vitamin D 3 is more potent [159] .
Systemic vitamin D status is reliably indicated by the serum level of 25-hydroxyvitamin D (25(OH)D) [70, 75, 78] , which reflects cutaneous photosynthesis and oral intake from both diet and supplements. Currently, there is no consensus on optimal levels of 25(OH)D. The 2010 Institute of Medicines (IOM) recommended that vitamin D deficiency (VDD) be defined as a 25(OH)D level <50 nmol/L, with a level >50 nmol/L representing vitamin D sufficiency (VDS) [139] . However, these guidelines have been criticized as being overly conservative by being based almost solely on studies of bone health [69, 167] . Higher 25(OH)D levels (e.g. >100 nmol/L) have been suggested to be necessary for optimal immune function and respiratory outcomes [17, 76, 78, 79, 166] .
For the purposes of this review we will use the most up to date recommendations from the Endocrine Society [76] e see Table 1 . Despite advances about the importance of vitamin D, VDD is widespread worldwide with recent estimates suggesting 1 billion people are affected worldwide [74] .
Although some foods contain vitamin D (mainly oily fish and fortified products), the major source for most humans is cutaneous photosynthesis under the influence of UV-B radiation from sunshine [74] . Therefore, VDD e like asthma e is more common in polluted, industrialized regions [115] , at high latitude [87] and in winter season [49] . Similar to asthma, body size and adiposity [51] , as well as darker skin pigmentation [38] , exposure to cigarette smoke [10, 73, 123, 153] , pollution [9, 89] and physical inactivity [73, 145, 163] are associated with decreased vitamin D status. Other determinants of vitamin D status include clothing and sunblock use [116] , inadequate diet and supplement usage as well as genetic variation [179] .
It is notable that the environmental changes attributable to the increase in asthma incidence and severity also cause VDD. The recent emergence of widespread VDD appears related to sun avoidance and seems to parallel the increased incidence of multiple diseases, including asthma.
Methods
References were identified by searches of MEDLINE, CINAHL, EMBASE and online Cochrane databases through January 2015. Keywords used included vitamin D and asthma, wheezing, airway inflammation, airway smooth muscle, and respiratory infection. Only manuscripts published in English are included. Articles were chosen according to their relevance for this review and their bibliographies were also searched for further references.
Results and discussion

Evidence linking vitamin D to asthma
There are two opposing theories regarding the effect of increasing 25(OH)D status in asthma. We will consider both Abbreviations list % predicated FEV 1 theories and present existing cross sectional and interventional evidence.
Is vitamin D detrimental in asthma?
Wjst and Dold first hypothesized that the introduction of vitamin D fortified foods was related to the asthma and allergy epidemic, suggesting that if protective antigen-reactive Th1 memory cells fail to develop, the subsequent predominance of Th2 cells can trigger allergic reactions [180] . This initial hypothesis was based on the observation that the introduction of vitamin D food fortification and specific vitamin D supplementation strategies seems to mirror the emergence of an asthma epidemic [175e178]. However, there is little evidence that 25(OH)D levels increased during this period and it is likely that several factors may even decreased 25(OH)D levels, including increased indoor time (i.e. indoor occupations and recreation) and increased sunscreen use. However, some animal work has seemingly supported the view that vitamin D is detrimental in asthma. VDR knockout mice do not develop airway inflammation or experimental asthma [174] . The same group went on to demonstrate that VDR expression is mandatory for the induction of lung inflammation [173] . Together these animal reports suggest that vitamin D and the VDR are important regulators of lung inflammation.
This initial hypothesis and animal model evidence was supported by limited human evidence. The first human report of potentially increased risk of atopy with vitamin D supplementation came in 1993. Peanut oil used for the pharmacological preparation of vitamin D to prevent peanut sensitization was associated with a markedly increased risk of allergen sensitization (OR ¼ 9.0; p < 0:003) compared to the supplement without allergen [44] . Later trials of supplementation with peanut oil or water with dissolved vitamin D alone or in combination with vitamin A demonstrated increased adverse allergic outcomes, including asthma [45, 97, 98] . The preparations used contained a combination of peanut oil as well as vitamins A and D, and therefore it is difficult to speculate on the individual contribution of each component. These early reports are supported by several prospective studies suggesting that early vitamin D supplementation may increase the risk of allergic disease among healthy infants [8, 59, 82, 130, 164] and that vitamin D may have detrimental effects on childhood lung function [42] and atopic disease [71, 181] .
However, the effect of vitamin D on immune and inflammatory signals may outweigh any potential shifting of Th1eTh2 balance and the majority of existing mechanistic [92] as well as observational data suggest that vitamin D repletion may be therapeutic in asthma. In fact, some authors have suggested that VDD may be responsible for the increase in allergic diseases and asthma prevalence worldwide [171, 107, 106] . However, interventional data has proved inconsistent (see below).
Epidemiologic data
There is decreased opportunity for vitamin D skin photosynthesis at higher latitude [74] . Therefore if vitamin D is truly important in asthmatic disease we can expect higher asthma incidence at higher latitude. Indeed, several reports have suggested that latitude is positively correlated to asthma [2, 56, 87, 95] and allergy [80] . However, not all ecological studies demonstrate this effect, with some studies noting no interaction [81, 114] , and others still an increased risk at lower latitude [131, 151, 170, 176, 187] . It should be noted that geographical latitude can only ever serve as a proxy for vitamin D status. Many factors affect asthma prevalence and may also vary by region, including healthcare resources, local population, genetics and pollution. Additionally, many factors affect the prevalence of VDD and may also vary by region and latitude, including diet and supplement use, religious clothing and sun habits. Indeed, VDD has been reported to common in low latitude countries with abundant sunshine [124, 52] .
Ethnic groups with darker skin have higher prevalence and severity of asthma when compared to those with lighter skin pigmentation residing in similar locations [57, 62, 65, 119] . Although, many factors could contribute to this observation (e.g. dietary habits, healthcare access), it is noteworthy that those with darker skin pigmentation have the same capacity but significantly decreased efficiency of cutaneous vitamin D photosynthesis upon exposure to UV-B [38] . Therefore, heavily pigmented individuals will typically have lower 25(OH)D status compared to lighter pigmented individuals residing at similar latitudes [68, 72] .
Nevertheless, a randomized trial of Norwegian children with atopic eczema demonstrated significant improvements after 4 weeks in a sunny climate [26] . Further, an observational study in 2007 of Spanish asthmatic children revealed that health related quality of life was highest in summer and lowest in autumn [60] . Indeed, sunny hours have been inversely associated with asthma prevalence [5] . Additionally, a subsequent longitudinal cohort study of 415 Australian children followed from birth to age 16, demonstrated that reported summer sun exposure was associated with reduced eczema and rhinitis but not inhalant allergen sensitization or asthma risk [90] . However, other studies note an increased risk of asthma and allergic disease with higher UV-B exposure [131] . These discrepancies can potentially be explained by recent trends in lifestyle e.g. sunscreen use and increased time spent indoors, which would decrease vitamin D photosynthesis. Considering that UV-B radiation is the major source of vitamin D for most populations, these observations appear to support a role for vitamin D in asthma.
Epidemiologic data demonstrate a positive association between 25(OH)D level and pulmonary function in healthy children [184, 185] , adults [19, 37, 158] , elderly males but not females [165] , asthmatics [154] , smokers [101] and those with COPD [86] . A detailed retrospective analysis from the UK demonstrated a linear association between 25(OH)D and lung function including both forced expiratory volume in 1 s (FEV 1 ) and forced vital capacity (FVC), which was consistent through the seasons and not fully explained by infections, adiposity or other lifestyle or socioeconomic measures [16] . A 20 year, Danish, prospective study with 18,507 subjects demonstrated that lower plasma 25(OH)D levels were associated with both lower lung function and faster decline in lung function (both FVC & FEV 1 ) [1] . Additionally, a crosssectional analysis of 650 mainly black, smokers revealed that there was no relationship between 25(OH)D and cathelicidin levels, but that lung function decrements were associated with low cathelicidin and were greatest among individuals with lower 25(OH)D levels [99] .
Supporting the idea that vitamin D is important in asthmatic and atopic disease, inverse associations between 25(OH)D and allergy [58, 83, 148] as well as asthma [107, 58, 88] have also been reported. However, other reports suggest that dietary vitamin D [127] and serum 25(OH)D concentrations [147] were not related to FEV 1 and that risk for atopic disease, including allergic rhinitis [181] and eczema [71] was higher with increased 25(OH)D. Taken together, most but not all existing epidemiological reports suggest that 25(OH)D may be an important and modifiable variable in the maintenance of lung health.
Case-control studies of vitamin D status and asthma
25 case control studies totaling 2568 asthmatic cases and 4376 controls have examined vitamin D intake, status as well as correlations with respiratory/atopic parameters in asthma cases compared to controls (see Table 2 ).
The case-control study by Carraro et al. deserves attention. The authors conducted a comprehensive observational study [120]
42 non-severe asthmatic children, 11 with severe asthma and 15 healthy, non-asthmatic children.
8e17 Padova, Italy 45 N A metabolomic approach to exhaled breath condensate (breathomics) revealed that the absence of ercalcitriol, (active metabolite of vitamin D 2 ) differentiated severe asthma from both non-severe asthma and healthy children. [29] regarding the metabolomics of exhaled breath condensate (breathomics) in severe asthmatic children vs. non-severe asthmatic children and healthy children. They observed that the absence of ercalcitriol (an active metabolite of vitamin D 2 ) differentiated severe asthma from both children with non-severe asthma and healthy children. This is perhaps the first report of vitamin D being recovered specifically in the lung. The authors speculate that children with severe asthma and treated with high-dose inhaled corticosteroids (ICS) may have insufficient vitamin D in the airways [29] . Observational studies, including case-control studies have several well-known limitations. Choice of controls can determine the observations and therefore even when efforts to match for confounding variables are made, the results can be biased. Further, even those with statistical adjustments, observational studies are limited by potential confounding. Therefore, it is impossible to ascertain whether an insufficient 25(OH)D level is responsible for reduced asthma control or that poor asthma control leads to decreased 25(OH)D status through acute inflammation as has been reported post-orthopedic surgery [138, 168] or reduced sun exposure due to asthma related inactivity. A recent in vivo study demonstrated that acute lung inflammation induced by exposure to house dust mite did not lead to altered 25(OH)D levels [33] suggesting that altered vitamin D status is not caused by allergic inflammation. However, children with wheezing, shortness of breath or allergy may avoid sunlight and outdoor activities [14, 15, 162] and therefore present with lower 25(OH)D.
Existing case-control studies regarding vitamin D and asthma have compared asthmatics to healthy controls by assessing measurements which were collected simultaneously and only at a single time point. Therefore it is not possible to determine temporal relationships between exposure and outcome. Further, many of these study populations exhibit widespread VDD and VDI and therefore it is difficult to comment on the effect of higher 25(OH)D on asthma parameters. Importantly, more than being interested in whether vitamin D intake and 25(OHOD status differs between asthmatic cases and non-asthmatic controls, the key question is whether vitamin D can influence asthma pathogenesis, severity and control. Because casecontrol studies can not answer these questions, these studies must be interpreted with caution. Hence, case-control studies are therefore placed low in the hierarchy of scientific evidence.
Cross-sectional studies of vitamin D status in asthma
Although, vitamin D may be of importance in adult asthma [105, 154] , the association of vitamin D deficiency with severity of asthma is reported to be particularly strong in children [63] e however this observation is not consistent [88] . Nevertheless, available cross-sectional data from 36 studies, involving 386,584 subjects suggest that low 25(OH)D is associated with poor control, increased exacerbation, reduced lung function and, increased medication usage in asthmatics (Table 3) .
These cross-sectional studies suffer from many of the same limitations as case-control studies. In particular, assessments were conducted simultaneously and typically only at a single time point only. Further, the widespread nature of VDD and VDI prevents the assessment of high 25(OH)D on asthma parameters. Similar to case-control studies, the results of cross-sectional reports must be interpreted with caution. Ultimately, these observational studies provide associations between vitamin D and asthma but can not determine cause or effect and hence are only a step in understanding relationships between vitamin D and respiratory outcomes.
Prospective studies of vitamin D status and asthma outcomes
In contrast to case-control and cross-sectional studies, prospective studies follow subjects who are similar but differ with respect to certain factors. These factors can be studied to determine how they affect certain outcomes. There are 7 post-natal prospective studies regarding asthma, involving a total of 14,041 subjects followed for 1e31 years (Table 4) .
Compared to observational studies, prospective cohort studies are superior regarding assessment of sequence between exposure and outcome. However, the longitudinal design of these studies means there is a lag between assessment of exposure and assessment of outcome. Because many factors influence both asthma pathogenesis and 25(OH)D levels and because 25(OH)D levels ae known to fluctuate over time, prospective studies too are limited in this context. Therefore interventional trials are best suited to study the effects of vitamin D and asthmatic disease.
Interventional data of vitamin D in asthma
Case-control, cross-sectional and prospective studies designs are interesting and provide insights into any potential relationship between vitamin D and asthma outcomes. However, intervention data, particularly from randomized, controlled trials designed to specifically assess the impact of vitamin D on asthma parameters provide far more robust information. There are 17 published trials of vitamin D supplementation in asthma involving 1578 asthmatics with varying doses and preparations of vitamin D followed for 4e52 weeks ( Table 5 ).
The idea that vitamin D therapy could be therapeutic in asthma and allergic disease dates back to the early 20th century. Vitamin D was only discovered around this time. This led to a successful treatment of rickets and interest in other conditions, including asthma and allergy. Viosterol (which contained ergosterol, the precursor to ergocalciferol e vitamin D 2 ) was the vehicle of choice for these early investigations into asthma.
An early pilot study involving a heterogenous group of 11 subjects with either non-atopic asthma (n ¼ 3), chronic uriticaria (n ¼ 2) or ragweed allergy þ asthma (n ¼ 6) treated with very large doses of viosterol (up to 1,380,000 IU bi-weekly for weeks to months) reported variable results in the Journal of the American Medical Association in 1933. In this pilot study, non-atopic asthmatics and subjects with uriticaria showed little improvement while subjects with ragweed allergy showed varying but obvious improvements [137] .
These observations led the same investigators to conduct a subsequent larger study focusing on 212 patients specifically with asthmatic allergic to ragweed. The treatments were high dose viosterol (120,000e300,000 IU/day, n ¼ 68) or high dose viosterol and pollen injection (n ¼ 144). In the viosterol only group, 82.4% experienced definite significant relief. In the viosterol þ pollen group, 96.5% had comparable degrees of relief. The authors wrote that: '92% of the entire series were definitely and significantly relieved'. Interestingly, despite the massive doses of vitamin D 2 utilized, hypercalcemia was not evident [136] .
These early American studies were followed up by some publications in small European journals in the mid 20th century [28, 85] . In 1976, a German group reported a double-blind, crossover trial of oral calcium þ vitamin D 2 (undescribed doses) on 12 patients with allergic bronchial asthma and airway obstruction. Within 60 min of application, a statistically significant reduction of airway resistance and intrathoracic gas volume, as well as an increase of FEV 1 and forced inspiratory volume in 1 s (FIV 1 ) was observed compared to placebo. It was concluded that calcium, given orally in combination with vitamin D 2 , causes a decrease of airway obstruction in patients with allergic bronchial asthma [161] .
These early trials are limited by the large doses of vitamin D used, use of vitamin D 2 as opposed to vitamin D 3 , sub-optimal trial design and missing details. Nevertheless and despite the inconsistent beneficial effects observed from these early trials, interest in the therapeutic potential of vitamin D in asthma seemed to decrease and the next asthma specific intervention trial, following multiple reports correlating vitamin D with worse asthma outcomes in human, animal and cell models, was not performed until 2009.
Before these vitamin D intervention trial, reports appeared suggesting an increased risk of atopy with peanut oil þ vitamins A and D. The first report of potentially increased risk of atopy with [150] 1024 asthmatic children 7e11 USA wide 28e48 N VDD was correlated with decreased lung function (prebronchodilator FEV 1 ) compared to children with VDI or VDS.
[182]
Asthmatic out-patients (number of subjects not specified)
Not reported San Juan, Puerto Rico 18 N 80% were VDD. 25(OH)D correlated positively with ACT score but negatively with PEFR.
[188]
(continued on next page) [142] 2815 children 10 Germany (4 separate cities) 48e51 N There was no association between 25(OH)D and either asthma or AR. [169] vitamin D supplementation came in 1993. Peanut oil used for the pharmacological preparation of vitamin D to prevent peanut sensitization was associated with a markedly increased risk of sensitization to allergen (OR ¼ 9.0; p < 0:003) compared to the supplement without allergen [44] . Later trials of supplementation with vitamins A and D dissolved in peanut oil and particularly when dissolved in water demonstrated increased adverse allergic outcomes, including asthma [45, 97, 98] . The preparations used contained a combination of peanut oil as well as vitamins A and D, and therefore it is difficult to speculate on the individual contributions.
Since a call to action for vitamin D intervention trials in asthma in 2009 [47] , several small trials have been published:
Majak et al. conducted a double-blind, randomized, placebocontrolled trial (DBRCT) to assess specific immunotherapy (SIT) in combination with ICS (prednisone 20 mg daily) þ either placebo or vitamin D 3 (1000 IU/week). This was a one-year trial at high latitude (51 N) and enrolled 54 asthmatic children allergic to house dust mites on SIT. Early administration of ICS prevented the benefits of SIT. However, the addition of low dose vitamin D 3 (equivalent to 143 IU/day) preserved the benefits of SIT, despite concomitant ICS use. Indeed, all negative clinical-and immunological-effects of prednisone were prevented by administration of low dose vitamin D 3 [111] . For more detail on the potential of vitamin D as an adjunct to anti-inflammatory therapy in asthma, see section 3.2.6 in partone of this review.
Urashima et al. conducted a DBRCT to assess the effectiveness of vitamin D 3 (2000 IU/d) vs. placebo in reducing influenza A incidence in 334 Japanese school children. This four-month study included physician diagnosed asthma exacerbations as a secondary outcome. Although an 83% reduction in asthma attacks with vitamin D was observed (RR: 0.17; 95% CI: 0.04, 0.73; p ¼ 0.006), only 26% (n ¼ 110) of the sample had physician diagnosed asthma. Additionally there was no assessment of 25(OH)D status or asthma severity at any stage [160] . Following up on their preliminary work, Majak et al. conducted a small, DBRCT of ICS vs. ICS þ vitamin D (500 IU/d). This was a 6 month trial conducted at high latitude (51 N) and enrolled 48 children with newly diagnosed asthma. There was a significant increase in asthma exacerbations in the placebo group (OR, 8.6; 95% CI, 2.1e34.6). However, the difference in serum 25(OH)D and asthma therapy assessment questionnaire (ATAQ) scores between the intervention and placebo group was very small and neither reached statistical significance [112] .
Retrospective, secondary analysis of pooled data obtained from previously published DBRCTs on 36 asthmatic children undergoing allergen immunotherapy revealed that higher serum 25(OH)D was associated with a more significant reduction in asthma symptoms and steroid use as well as higher TGF-a production and Foxp3 induction [113] .
Lewis et al. conducted a 1 year DBRCT to examine whether increased 25(OH)D levels e either through seasonal variation or supplementation -could affect asthma. In this one year study of 20 children with chronic persistent asthma, half were given 1000 IU vitamin D 3 /d while the other half were given placebo and seasonal variation in 25(OH)D was observed. 19 of the 20 enrolled children were VDI at baseline. Although, vitamin D supplementation did not affect ACT score or FEV 1 , all children were well controlled at baseline. Further, pooled data on all 25(OH)D measurements and corresponding ACT scores revealed a significant positive correlation (r ¼ 0.25, p < 0.05) [104] .
Yadav & Mittal conducted a DBRCT to assess the effectiveness of vitamin D 3 (60,000 IU/month) vs. placebo in improving asthma parameters. Compared to the placebo group, the vitamin D group experienced reduced exacerbations (p ¼ 0.011) and steroid requirements (p ¼ 0.013) and increased expiratory flow rate, however there was no report of 25(OH)D levels. The authors concluded: 'Vitamin D has a definite role in the management of moderate to severe persistent bronchial asthma as an adjunct to standard treatment' [183] .
Arshi et al. conducted a 3 arm randomized trial of ICS vs. ICS plus long-acting b-agonist (LABA) þ vitamin D 3 vs. ICS plus LABA þ placebo. This 24 week trial included asthmatics aged 10e50y and the vitamin D dose was 100,00 IU bolus intramuscularly (IM) plus 50,000 IU orally weekly. Although, percentage predicted FEV 1 improved in both groups, the improvement was significantly greater in the vitamin D group at 24 weeks (p < 0.001) [6] . Baris et al. conducted a 3 arm, randomized trial of subcutaneous immunotherapy (SCIT) alone (n ¼ 15), or with vitamin D 3 supplementation (650 IU/day; n ¼ 17), or pharmacotherapy alone (n ¼ 18). Although both SCIT groups fared better than pharmacotherapy alone at the end of 1 year, some favorable outcomes in the vitamin D group were noted including better asthma controls as indicated by corticosteroid treatment discontinuation in a greater percentage of patients (p ¼ 0.02) [12] .
Bar Yoseph et al. conducted a DBRCT of vitamin D supplementation (14,000 IU/week) vs. placebo for 6 weeks in asthmatic children. There was no change in IgE, eosinophil count, high sensitivity C reactive protein, fraction of exhaled nitric oxide levels or provocation dose of methacholine require to induce a 20% drop in FEV 1 between he vitamin D or placebo groups. Exhaled breath condensate cytokines, including IL4, IL5, IL10, IL17, and interferon gamma changed in both groups but there was no difference [11] .
Castro et al. reported findings from the large Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma (VIDA). Compared to placebo, a baseline 100,000 IU vitamin D 3 bolus followed by 4000 IU daily for 28 weeks had no significant effect on the overall rate of first treatment failure or exacerbation in patients with asthma and VDI. However, at 28 weeks, there was a significant difference in cumulative ciclesonide (a glucocorticoid) dosing between the vitamin D and placebo groups (111.3 vs.
126.2 mg/day; p ¼ 0.02). Additionally, in the 82% of the vitamin D supplementation group who reached VDS, there were significant reductions in exacerbations and the rate of first treatment failure [30] . Due to the baseline bolus dose and the moderate-high daily dose, it was surprising that 18% of the vitamin D group did not reach VDS, which may have affected the results. This may be due to the obese nature of the cohort (mean BMI ¼ 32 kg/m 2 ) or malabsorption, metabolism, or compliance issues with vitamin D. was administered twice daily to the 1,25D group (n ¼ 13). Although there was no significant difference in %FEV 1 , a within-group comparison showing the change in lung function during the initial screening in response to 2-week oral prednisolone vs. the response to an identical course of prednisolone plus either placebo or 1,25D revealed a modest but significant improvement in absolute and predicted FEV 1 with 1,25D compared to placebo (p ¼ 0.03). There was no observed benefit in patients randomized to receive 1,25D before the second course of prednisolone, suggesting that 1,25D alone had no effect on lung function. A trend for a positive correlation between baseline 25(OH)D and change in predicted lung function following prednisolone (r ¼ 0.56, p ¼ 0.08) was observed. Additionally, following prednisolone, there was a greater improvement in % FEV 1 in VDS compared to VDI subjects (p ¼ 0.03) [126] . de Groot et al. conducted a DBRCT comparing a large bolus of vitamin D 3 ( 400,000 IU) to placebo. On a group level, there was no significantly effect on sputum neutrophils or eosinophils with vitamin D or placebo. However, subgroup analysis of subjects with airway eosinophilia at baseline revealed that vitamin D significantly decreased sputum eosinophils from a median of 41%e11.8% compared to an increase from 51.8% to 63.3% in patients receiving placebo (p ¼ 0.034). Vitamin D treatment also resulted in slightly better Asthma Control Questionnaire scores (p ¼ 0.08) [43] .
Although some of these interventional trials suggest a benefit of vitamin D repletion, they are limited by small sample sizes, short duration and potentially inadequate vitamin D dose. Nevertheless, a recent systematic review and meta-analysis in paediatric asthmatics noted a statistically significant reduction in asthma exacerbation with vitamin D supplementation (RR 0.41, CI 0.27e0.63) [134] . However, the need for adequately powered trials utilizing adequate vitamin D dosing persists.
Why is data from human studies inconsistent?
The majority of existing epidemiologic and observational data suggest that vitamin D intake and/or status may be of importance in asthmatic disease. However, not all studies are in agreement with some studies demonstrating no benefit from increased vitamin D intake and/or status, while other reports suggest inferior asthmatic outcomes associated with higher vitamin D. Vitamin D represents a unique nutrient with many complexities. Although some studies directly measure vitamin D status, other studies record vitamin D intake through food frequency questionnaires, which can be a poor predictor of both vitamin D intake and 25(OH) D status. Unlike other nutrients, the major source of vitamin D for most people is not through diet, but from exposure to UV-B. Therefore vitamin D status displays marked variation depending on local weather conditions and individual sun behaviors e.g. sunscreen use, time indoors etc. Most studies assess sun habits and vitamin D status or intake at a single time point only. Human behavior and season are variables, which change often and can influence both asthma and vitamin D outcomes. Therefore epidemiologic and observational studies are limited regarding asthma and vitamin D.
Well designed, long term prospective and interventional studies regarding vitamin D and asthmatic disease can provide more robust evidence. To date there is a lack of these studies in asthma (reviewed in Tables 4 and 5 respectively). However, again the results of existing prospective studies are conflicting. These prospective studies have relied on a single measurement of vitamin D status or intake with asthmatic outcomes assessed up to 31 years later. Despite efforts to control for relevant, non-vitamin D confounders, it is impossible to discount variables other than vitamin D contributing to the observations. Similarly, vitamin D intervention studies to date provide inconsistent results. There have been 17 vitamin D intervention trials in asthma to date ( Table 5 ). These intervention trials differed in terms of trial design, vitamin D dosing, outcome measures and trial duration, which may help explain the inconsistencies.
Conclusions
What is the optimal vitamin D intakes and serum 25(OH) level for asthma?
The recommendations for optimal vitamin D intake and serum 25(OH)D levels are controversial. The 2010 IOM report suggests a recommended daily allowance of 600 IU for healthy subjects aged >1y and a target serum 25(OH)D of >50 nmol/L [139] . However this report was based almost exclusively on skeletal considerations and has been criticized by experts in the vitamin D field [69, 167] . Some reports observed a plateau effect of serum 25(OH)D at 50 nmol/L regarding exacerbations in asthmatics [13] . However, others suggest a serum 25(OH)D level >100 nmol/L may be required for optimal immunological and respiratory outcomes [17, 76, 78, 79, 166] . Conversely, both high and low 25(OH)D levels have been associated with adverse outcomes in terms of increased aeroallergen sensitization [140] , elevated IgE levels [83] , and adverse changes in lung function [156] raising the possibility that an optimal level of 25(OH) D exists regarding asthma and that levels above or below are detrimental.
It has been argued that in populations with limited sun exposure that the current vitamin D recommendations are inadequate for non-skeletal effects, and that intakes 2000 IU/day may be required [74, 76] . For example, a 500 IU supplement of vitamin D 3 daily for 6 months was insufficient to increase serum 25(OH)D in asthmatic children at 51 N [113] . In asthmatic children treated with 1000 IU for 12 months only 50% reached vitamin D sufficiency defined as >75 nmol/L [104] . Indeed, the Endocrine Society recommended vitamin D supplements of up to 4000 IU/day for adults [76] .
UV-B is the major source of vitamin D for most people, even at high latitude [74] but with lifestyle changes and concerns about sun damage, sun exposure has decreased contributing to widespread VDI. However, achievable sunlight exposure may not be sufficient for adequate 25(OH)D levels, particularly in urban and/or heavily pigmented subjects [21] . Because vitamin D is naturally found in few foods (mainly oily fish) and few food products are fortified adequately (mainly dairy and cereal products), it is difficult to achieve an adequate vitamin D status through diet al.one. Indeed, dietary intake of vitamin D is typically inadequate [18] , including among asthmatic cohorts [25] . Further, a randomized controlled trial demonstrated that diet was inadequate to achieve sufficient serum 25(OH)D [41] .
Although cod liver oil contains vitamin D 3 , its use has been associated with increased asthma incidence [81, 110, 129] possibly due to its high vitamin D content [27] and therefore may not represent a suitable vehicle to increase vitamin D intake and serum 25(OH)D. Additionally, vitamin D 2 is not as effective as vitamin D 3 in maintaining serum 25(OH) levels [159] .
Future recommendations
Despite, recent widespread publicity, vitamin D deficiency remains highly prevalent throughout the world [74] . Here we have presented human observational and interventional data regarding vitamin D and asthma. Despite the recent advances in our understanding of the vitamin D pathway and its potential implications for allergic and immune disorders such as asthma, many questions remain:
Is widespread vitamin D supplementation detrimental in asthma as initially hypothesized or beneficial as mechanistic and observational work suggest?
Has vitamin D replacement therapy a role as an adjunct to antiinflammatory therapy or immunotherapy in asthma?
Is the effect of vitamin D supplementation limited to a specific asthma phenotype/endotype? And if so, which one?
When is the therapeutic age range to exploit the potential benefits of vitamin D supplementation in asthma?
Should 25(OH)D be routinely measured in asthma?
What is the desired serum 25(OH)D level for a potential therapeutic effect in asthma? What is the best strategy to achieve this desired serum 25(OH)D level? Does peri-natal vitamin D supplementation reduce the risk of developing asthma? The focus of the current manuscript was to review existing human evidence that vitamin D may be of importance in asthmatic disease. We have not comprehensively reviewed studies of perinatal studies of vitamin D status or intake. Existing trials in this area are inconsistent, probably owing to important differences in study design for example measuring vitamin D status versus reported vitamin D intake. Additionally vitamin D levels are known to fluctuate over time and are rapidly and significantly altered by modifiable human behaviors such as location, sun behaviors and supplement use. Therefore, the importance of a single vitamin D assessment in early childhood or pregnancy is of debatable importance regarding future asthmatic outcomes. However manipulating 25(OH)D status holds promise for primary prevention of asthma as recent reviews suggest [121, 135] . Is ultraviolet radiation a powerful immunomodulator in asthmatic disease where 25(OHJ)D status merely reflects ultraviolet exposure? For example acute ultraviolet exposure caused systemic immunosuppression in the absence of increased 25(OH)D in mice [64] This fascinating concept cannot be discounted currently and is supported by several, recent animal studies whereby ultraviolet exposure inhibited asthmatic disease [117, 118] . Relevant human evidence comes from inverse associations with diverse respiratory tract symptoms [155] , RSV incidence [172, 186] and risk of invasive pneumococcal disease associated with UV-B (White et al., 2009). We briefly presented human evidence suggesting a benefit of sunlight in asthmatic disease above in section 3.1.2 New therapeutic options for wheezing disorders, and particularly steroid resistant asthma are needed. Serum 25(OH)D level is a novel and modifiable potential risk marker for severe asthma exacerbations [55] . Taken together existing mechanistic and observational data support a role for vitamin D as an important factor in asthma and infection. However, results from existing clinical trials provide heterogeneous findings.
Vitamin D supplementation potentially represents a low-cost, low-risk method to treat and prevent asthma and therefore further exploration of the effect of vitamin D supplementation is encouraged. Future trials should utilize adequate doses of vitamin D 3 preparations for interventions of sufficient duration. Appropriate trial duration appears likely to be >12 months considering the half life of 25(OH)D is approximately 2e3 weeks [75] as well as the natural seasonal variation in asthma and infection. Additionally, because reported vitamin D intake and sun exposure are unreliable, 25(OH)D should be measured, preferably on more than one occasion. This will also help determine optimal 25(OH)D levels and decrease risk of vitamin D toxicity (VDT). VDT is rare and has most reports of VDT have resulted from industrial accidents [4] . Nevertheless supraphysiological 25(OH)D levels (>375 nmol/L), which are a possibility with extended use of inappropriately high doses of vitamin D (10,000 IU/d), can cause hypercalcemia and increased risk of falls [144] .
The data reviewed herein suggest that supplementation with moderate doses (e.g. 1000 IU/d) of vitamin D 3 may be appropriate for maintenance of bone health in asthmatics, particularly steroid users. However, existing data does not yet definitively support a role for supplemental vitamin D therapy as a adjunct strategy in asthmatic disease. Despite limited evidence, an adverse effect of widespread vitamin D supplementation can not be discounted and therefore caution is advised until more definitive evidence is available.
Childhood asthma and steroid resistant asthma are key underexplored areas where vitamin D based interventions may provide benefit. Only the results of well-designed, clinical trials can elude as to effects of vitamin D therapy asthma. Indeed there has been a call to action for well-designed intervention trials of vitamin D supplementation to assess its role in preventing and treating asthma [47] . Ongoing longitudinal studies and clinical trials should help ultimately answer some of the existing questions.
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